LA MARCA, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.912
EU - Europa 6.282
AS - Asia 3.005
OC - Oceania 44
AF - Africa 39
SA - Sud America 37
Continente sconosciuto - Info sul continente non disponibili 15
Totale 29.334
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.843
GB - Regno Unito 2.126
IT - Italia 1.088
SE - Svezia 1.011
HK - Hong Kong 926
CN - Cina 917
DE - Germania 635
UA - Ucraina 536
SG - Singapore 480
TR - Turchia 344
BG - Bulgaria 235
FI - Finlandia 194
FR - Francia 106
IN - India 68
RO - Romania 53
ID - Indonesia 51
CA - Canada 50
ES - Italia 42
RU - Federazione Russa 40
AU - Australia 34
IE - Irlanda 34
JP - Giappone 33
IR - Iran 32
NL - Olanda 29
KR - Corea 28
VN - Vietnam 27
CZ - Repubblica Ceca 25
LT - Lituania 23
BR - Brasile 21
BE - Belgio 20
PH - Filippine 16
MX - Messico 15
PK - Pakistan 15
CH - Svizzera 14
MY - Malesia 14
DZ - Algeria 11
TH - Thailandia 11
DK - Danimarca 10
NZ - Nuova Zelanda 10
PL - Polonia 10
EG - Egitto 9
CL - Cile 8
LV - Lettonia 8
BD - Bangladesh 7
EU - Europa 7
MA - Marocco 7
AL - Albania 6
HR - Croazia 6
UZ - Uzbekistan 6
IL - Israele 5
NO - Norvegia 5
SC - Seychelles 5
TW - Taiwan 5
A2 - ???statistics.table.value.countryCode.A2??? 4
CO - Colombia 4
IQ - Iraq 4
MD - Moldavia 4
NP - Nepal 4
AT - Austria 3
GR - Grecia 3
HU - Ungheria 3
NG - Nigeria 3
PT - Portogallo 3
SI - Slovenia 3
XK - ???statistics.table.value.countryCode.XK??? 3
AR - Argentina 2
CR - Costa Rica 2
KW - Kuwait 2
LB - Libano 2
LK - Sri Lanka 2
PE - Perù 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
A1 - Anonimo 1
AM - Armenia 1
BZ - Belize 1
EE - Estonia 1
ET - Etiopia 1
IS - Islanda 1
JM - Giamaica 1
JO - Giordania 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LY - Libia 1
MM - Myanmar 1
SA - Arabia Saudita 1
SY - Repubblica araba siriana 1
ZA - Sudafrica 1
ZW - Zimbabwe 1
Totale 29.334
Salva come PNG Salva come JPEG
Città #
Fairfield 3.902
Woodbridge 1.885
Ashburn 1.868
Southend 1.737
Houston 1.549
Seattle 1.466
Cambridge 1.303
Wilmington 1.148
Chandler 1.125
Hong Kong 907
Jacksonville 893
Ann Arbor 758
Dearborn 680
Nyköping 675
Modena 374
Singapore 340
Beijing 313
San Diego 285
Princeton 237
Sofia 232
Izmir 205
Eugene 193
Boardman 152
Helsinki 121
Bremen 119
London 95
New York 88
Shanghai 74
Redwood City 68
Milan 52
Rome 48
Jakarta 47
Guangzhou 43
Falls Church 40
Norwalk 37
Kilburn 34
Dublin 32
Fremont 32
Iasi 31
Nanjing 30
Hefei 28
Toronto 28
Bologna 27
Kunming 24
Jinan 22
Parma 22
Dong Ket 20
Des Moines 19
Cortona 18
San Mateo 17
Brussels 16
Frankfurt am Main 16
Prescot 16
Chiswick 15
Augusta 14
Chicago 14
Fiorano Modenese 14
Melbourne 14
Olomouc 13
Tokyo 13
Hounslow 12
Leawood 12
Nanchang 12
Barcelona 11
Fuzhou 11
Jönköping 11
Appignano 10
Huddinge 10
Mountain View 10
Paris 10
Philadelphia 10
Suwon 10
São Paulo 10
Ankara 9
Munich 9
Naples 9
Turin 9
Auckland 8
Hanover 8
Indiana 8
Islington 8
Los Angeles 8
Madrid 8
Riga 8
Shenyang 8
Wandsworth 8
Bangalore 7
Castelnovo 7
Chiang Mai 7
Dongguan 7
Florence 7
Grafing 7
Hangzhou 7
Hanoi 7
Ottawa 7
Padova 7
Rimini 7
Sesto Fiorentino 7
Southwark 7
Veracruz 7
Totale 23.933
Salva come PNG Salva come JPEG
Nome #
Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial 433
Vitamin D and ovarian reserve: making clinical decisions 235
LH and hCG Action on the Same Receptor Results in Quantitatively and Qualitatively Different Intracellular Signalling 231
Anti-Mullerian hormone (AMH): what do we still need to know? 223
The anti-Müllerian hormone (AMH) acts as a gatekeeper of ovarian steroidogenesis inhibiting the granulosa cell response to both FSH and LH 214
The menstrual cycle regularization following d-chiro-inositol treatment in PCOS women: a retrospective study 211
Evidence for expression and functionality of FSH and LH/hCG receptors in human endometrium 204
Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). 203
How Much Does AMH Really Vary in Normal Women? 202
FSHR polymorphism p.N680S mediates different responses to FSH in vitro 201
Gene expression profiles of human granulosa cells treated with bioequivalent doses of corifollitropin alfa (CFA) or recombinant human follicle-stimulating hormone (recFSH) 201
From a circle to a sphere: the ultrasound imaging of ovarian follicle with 2D and 3D technology 199
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 197
Individualization of the FSH starting dose in IVF/ICSI cycles using the antral follicle count 197
Female age, serum antimüllerian hormone level, and number of oocytes affect the rate and number of euploid blastocysts in in vitro fertilization/intracytoplasmic sperm injection cycles 195
New strategies of ovarian stimulation based on the concept of ovarian follicular waves: From conventional to random and double stimulation 195
Age-specific nomogram for the decline in antral follicle count throughout the reproductive period 195
Polymorphisms in gonadotropin and gonadotropin receptor genes as markers of ovarian reserve and response in in vitro fertilization 191
Embryo quality and implantation rate in two different culture media: ISM1 versus Universal IVF Medium. 190
Age-specific reference values for serum FSH and estradiol levels throughout the reproductive period 190
Modulation of gonadotrophin induced steroidogenic enzymes in granulosa cells by d-chiroinositol 190
Prediction of age at menopause from assessment of ovarian reserve may be improved by using body mass index and smoking status. 189
MATER protein as substrate of PKCepsilon in human cumulus cells. 188
The ovarian response to controlled stimulation in IVF cycles may be predictive of the age at menopause 188
Elevated levels of nitrous dioxide are associated with lower AMH levels: A real-world analysis 188
Adnexal Torsion during Pregnancy after Oocyte In Vitro Maturation and Intracytoplasmic Sperm Injection Cycle. 185
Ovarian response markers lead to appropriate and effective use of corifollitropin alpha in assisted reproduction 184
Reference values in ovarian response to controlled ovarian stimulation throughout the reproductive period 179
Age-related normograms of serum antimüllerian hormone levels in a population of infertile women: a multicenter study 177
Live birth rates in the different combinations of the Bologna criteria poor ovarian responders: a validation study 176
Primary ovarian insufficiency: autoimmune causes. 174
The anti-Müllerian hormone (AMH) induces forkhead box L2 (FOXL2) expression in primary culture of human granulosa cells in vitro 174
Periodontal disease and nitric oxide levels in low risk women with preterm labor 173
Nitric Oxide concentration in endometrial washing throughout the menstrual cycle 173
ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria 173
Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice 172
Utero-vaginal anastomosis in the treatment of cervical atresia 171
Increased risk of preterm birth and low birthweight with very high number of oocytes following IVF: an analysis of 65 868 singleton live birth outcomes 170
Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles 170
Anti-Müllerian hormone-based prediction model for a live birth in assisted reproduction 169
Evidence for cycle-dependent expression of follicle-stimulating hormone receptor in human endometrium 167
Seminal plasma total antioxidant capacity and semen parameters in patients with varicocele 165
External validation of anti-Müllerian hormone based prediction of live birth in assisted conception 164
A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles 164
Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI) 163
A novel transnational fresh oocyte donation (TOD) program based on transport of frozen sperm and embryos 162
Does plasma insulin level affect ovarian response to exogenous administration of follicle-stimulating hormone in women without polycystic ovary syndrome? 161
The physiology and clinical utility of anti-Mullerian hormone in women 161
Basal progesterone level as the main determinant of progesterone elevation on the day of hCG triggering in controlled ovarian stimulation cycles 161
Human ovarian tissue cryopreservation: effect of sucrose concentration on morphological features after thawing 160
Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome 160
Recombinant LH administration in subsequent cycle after "unexpected" poor response to recombinant FSH monotherapy 159
Corrigendum to “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV” [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019) 159
Thyroid function in early pregnancy II: Paradoxical growth hormone response to thyrotropin-releasing hormone 159
Surgical treatment of ovarian dermoid cysts 159
Perinatal outcomes following IVF with use of donor versus partner sperm 159
Possibilities and Limits of Ovarian Reserve Testing in ART 158
Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: An individual patient data approach 158
How to personalize ovarian stimulation in clinical practice 157
Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome 157
Insulin sensitizing agents and their effect on adrenal androgens?: the reply 156
Understanding the perceptions of and emotional barriers to infertility treatment: a survey in four European countries 156
The ovarian follicular pool and reproductive outcome in women. 155
Rectovaginal fistula repair using fascia graft of autologous abdominal muscles 153
Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients 152
Anti-Müllerian hormone: clairvoyance or crystal clear? 152
Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinaemia or lean normoinsulinaemia 152
The role of ovarian suspension in endometriosis surgery: a randomized controlled trial 152
The management of vaginal agenesis: report of 104 cases 152
Anti-Mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology 151
Adrenal adenocarcinoma and empty sella syndrome in a 37-year-old woman 151
Soluble L-selectin levels during controlled ovarian hyperstimulation 151
Advances in the Molecular Pathophysiology, Genetics, and Treatment of Primary Ovarian Insufficiency 151
The combination of genetic variants of the FSHB and FSHR genes affects serum FSH in women of reproductive age 151
Recombinant human leptin in women with hypothalamic amenorrhea. 149
Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome 149
Clinical application of a nomogram based on age, serum FSH and AMH to select the FSH starting dose in IVF/ICSI cycles: a retrospective two-centres study 149
Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation 148
Hormonal and ultrasound markers of ovarian function in a woman with a balanced 1;11 translocation 148
Whatever its variability, antimüllerian hormone remains the most stable hormonal predictor 148
Normal serum anti-Müllerian hormone levels in the general female population and the relationship with reproductive history 148
Short-term treatment of uterine fibromyomas with danazol 148
Ultrastructural and DNA fragmentation analyses in swim-up selected human sperm 147
Administration of somatostatin analogue reduces uterine and myoma volume in women with uterine leiomyomata 147
Anti-mullerian hormone in premenopausal women and after spontaneous or surgically induced menopause 147
Veralipride administered in combination with raloxifene decreases hot flushes and improves bone density in early postmenopausal women 147
The journey from the old to the new AMH assay: how to avoid getting lost in the values 146
Reply: The two sides of the individualization of controlled ovarian stimulation 146
The use of ovarian reserve markers in IVF clinical practice: a national consensus 146
Progestin effects on epidermal growth factor receptor (EGFR) endometrial expression in normal and hyperplastic endometrium 146
Rectus abdominis muscle endometriosis: Case report and review of the literature 146
Thyroid function in early pregnancy I: Thyroid-stimulating hormone response to thyrotropin-releasing hormone 145
Gestrinone in the treatment of uterine leiomyomata: effects on uterine blood supply 144
Effects of estradiol alone or in combination with cyproterone acetate on carotid artery pulsatility index in postmenopausal women 144
Chronic endometritis in recurrent implantation failure: Use of prednisone and IVF outcome 142
The cardiovascular risk factor homocysteine is not elevated in young women with hyperandrogenism or hypoestrogenism 142
Low-dose danazol after combined surgical and medical therapy reduces the incidence of pelvic pain in women with moderate and severe endometriosis 141
Clomiphene citrate increases insulin-like growth factor binding protein-1 and reduces insulin-like growth factor-I without correcting insulin resistance associated with polycystic ovarian syndrome 141
Total abdominal hysterectomy: A randomized study comparing two techniques 141
Normal serum concentrations of anti-Müllerian hormone in women with regular menstrual cycles 140
Totale 17.003
Salva come PNG Salva come JPEG
Categoria #
all - tutte 137.283
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 137.283
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20206.073 0 0 0 476 749 1.118 1.224 794 817 311 384 200
2020/20216.127 572 353 511 521 769 374 570 871 261 699 353 273
2021/20224.566 176 862 513 160 84 175 345 216 415 356 872 392
2022/20233.625 454 416 349 293 473 434 82 308 414 39 174 189
2023/20243.007 95 153 122 270 479 180 510 456 68 95 131 448
2024/2025583 260 89 107 127 0 0 0 0 0 0 0 0
Totale 29.746